Author: George Medicines

Posted Date:

April 22, 2026

George Medicines: New England Journal of Medicine publishes global stroke outcomes trial that demonstrated reduction of risk for recurrent stroke by almost 40% with GMRx2 in patients with previous intracerebral hemorrhage

George Medicines

April 22, 2026
George Medicines extends global commercialization of GMRx2 into Australia and New Zealand with Arrotex licensing agreement

George Medicines

March 16, 2026
George Medicines signs exclusive licensing agreement with Ahngook Pharmaceutical to commercialize GMRx2 in Korea

George Medicines

March 11, 2026
George Medicines advances its global commercial strategy for GMRx2 with an exclusive licensing agreement with Orient EuroPharma in Southeast Asia

George Medicines

February 25, 2026